Literature DB >> 19223630

Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.

Manuel Cuenca-Estrella1, Alicia Gomez-Lopez, Emilia Mellado, Araceli Monzon, Maria J Buitrago, Juan L Rodriguez-Tudela.   

Abstract

A collection of 2,278 isolates belonging to 86 different fungal species was tested with micafungin and eight other drugs using the EUCAST procedures. Micafungin was active against species of Candida and Aspergillus (even azole-resistant species) as well as Penicillium spp., Scedosporium apiospermum, and Acremonium spp. It was inactive for species of Basidiomycota and Mucorales and for multiresistant species such as those of Fusarium.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19223630      PMCID： PMC2681500          DOI： 10.1128/AAC.01543-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

1.  Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.

Authors:  Frank C Odds; Mary Motyl; Roberto Andrade; Jacques Bille; Emilia Cantón; Manuel Cuenca-Estrella; Amanda Davidson; Christian Durussel; David Ellis; Elyse Foraker; Annette W Fothergill; Mahmoud A Ghannoum; Robert A Giacobbe; Miguel Gobernado; Rosemary Handke; Michel Laverdière; Wendy Lee-Yang; William G Merz; Luis Ostrosky-Zeichner; Javier Pemán; Sophia Perea; John R Perfect; Michael A Pfaller; Laurie Proia; John H Rex; Michael G Rinaldi; Juan-Luis Rodriguez-Tudela; Wiley A Schell; Christine Shields; Deanna A Sutton; Paul E Verweij; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

2.  Antifungal susceptibility of 596 Aspergillus fumigatus strains isolated from outdoor air, hospital air, and clinical samples: analysis by site of isolation.

Authors:  J Guinea; T Peláez; L Alcalá; M J Ruiz-Serrano; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds.

Authors: 
Journal:  Clin Microbiol Infect       Date:  2008-10       Impact factor: 8.067

4.  Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.

Authors:  M A Pfaller; D J Diekema; L Ostrosky-Zeichner; J H Rex; B D Alexander; D Andes; S D Brown; V Chaturvedi; M A Ghannoum; C C Knapp; D J Sheehan; T J Walsh
Journal:  J Clin Microbiol       Date:  2008-06-25       Impact factor: 5.948

5.  National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.

Authors:  Shunji Takakura; Naoko Fujihara; Takashi Saito; Toyoichiro Kudo; Yoshitsugu Iinuma; Satoshi Ichiyama
Journal:  J Antimicrob Chemother       Date:  2003-12-19       Impact factor: 5.790

6.  Susceptibility of Pseudallescheria boydii and Scedosporium apiospermum to new antifungal agents.

Authors:  Jingsi Zeng; Katsuhiko Kamei; Yuecheng Zheng; Kazuko Nishimura
Journal:  Nihon Ishinkin Gakkai Zasshi       Date:  2004

7.  Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

Authors:  Luis Ostrosky-Zeichner; John H Rex; Peter G Pappas; Richard J Hamill; Robert A Larsen; Harold W Horowitz; William G Powderly; Newton Hyslop; Carol A Kauffman; John Cleary; Julie E Mangino; Jeannette Lee
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

8.  Comparison of two methods and three end points in determination of in vitro activity of micafungin against Aspergillus spp.

Authors:  Sevtap Arikan; Pinar Yurdakul; Gulsen Hascelik
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

9.  Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Emilia Mellado; Maria J Buitrago; Araceli Monzon; Juan Luis Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

10.  Micafungin activity against Candida albicans with diverse azole resistance phenotypes.

Authors:  Theresa S Richards; Brian G Oliver; Theodore C White
Journal:  J Antimicrob Chemother       Date:  2008-04-23       Impact factor: 5.790
View more
  19 in total

1.  Frequency of voriconazole resistance in vitro among Spanish clinical isolates of Candida spp. According to breakpoints established by the Antifungal Subcommittee of the European Committee on Antimicrobial Susceptibility Testing.

Authors:  M Cuenca-Estrella; A Gomez-Lopez; I Cuesta; O Zaragoza; E Mellado; J L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

2.  New Fks hot spot for acquired echinocandin resistance in Saccharomyces cerevisiae and its contribution to intrinsic resistance of Scedosporium species.

Authors:  Michael E Johnson; Santosh K Katiyar; Thomas D Edlind
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

Review 3.  Regulatory circuitry governing fungal development, drug resistance, and disease.

Authors:  Rebecca S Shapiro; Nicole Robbins; Leah E Cowen
Journal:  Microbiol Mol Biol Rev       Date:  2011-06       Impact factor: 11.056

4.  Improved detection of Candida sp. fks hot spot mutants by using the method of the CLSI M27-A3 document with the addition of bovine serum albumin.

Authors:  Guillermo Garcia-Effron; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2011-03-07       Impact factor: 5.191

5.  Risk factors for fluconazole-resistant candidemia.

Authors:  José Garnacho-Montero; Ana Díaz-Martín; Emilio García-Cabrera; Maite Ruiz Pérez de Pipaón; Clara Hernández-Caballero; Javier Aznar-Martín; José M Cisneros; Carlos Ortiz-Leyba
Journal:  Antimicrob Agents Chemother       Date:  2010-05-24       Impact factor: 5.191

Review 6.  The challenge of managing fusariosis.

Authors:  Maged Muhammed; Jeffrey J Coleman; Herman A Carneiro; Eleftherios Mylonakis
Journal:  Virulence       Date:  2011-03-01       Impact factor: 5.882

7.  A case of Schizophyllum commune sinusitis following unrelated cord blood transplantation for acute lymphoblastic leukemia.

Authors:  Takashi Toya; Akihito Shinohara; Keita Tatsuno; Sachiko Seo; Yasuhito Nannya; Motoshi Ichikawa; Koichi Makimura; Kyoji Moriya; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2013-05-18       Impact factor: 2.490

8.  Species identification and antifungal susceptibility patterns of species belonging to Aspergillus section Nigri.

Authors:  Laura Alcazar-Fuoli; Emilia Mellado; Ana Alastruey-Izquierdo; Manuel Cuenca-Estrella; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2009-07-27       Impact factor: 5.191

9.  Species distribution and susceptibility profile to fluconazole, voriconazole and MXP-4509 of 551 clinical yeast isolates from a Romanian multi-centre study.

Authors:  B Minea; V Nastasa; R F Moraru; A Kolecka; M M Flonta; I Marincu; A Man; F Toma; M Lupse; B Doroftei; N Marangoci; M Pinteala; T Boekhout; M Mares
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-09-16       Impact factor: 3.267

10.  Review of the pharmacology and clinical studies of micafungin.

Authors:  Alison M Bormann; Vicki A Morrison
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.